Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

205
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
205
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

244
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
244
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

212
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
212

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A single nucleotide polymorphism in LRP2 is associated with susceptibility to Alzheimer's disease in the Chinese population.

Clinica chimica acta; international journal of clinical chemistry·2010
Same author

Three-component assembly and divergent ring-expansion cascades of functionalized 2-iminooxetanes.

Angewandte Chemie (International ed. in English)·2010
Same author

Prokaryotic expression and potential application of the truncated PCV-2 capsid protein.

Virologica Sinica·2010
Same author

Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus.

The Journal of rheumatology·2010
Same author

Peptide dendrimers as efficient and biocompatible gene delivery vectors: Synthesis and in vitro characterization.

Journal of controlled release : official journal of the Controlled Release Society·2010
Same author

The amplification and evolution of orthologous 22-kDa α-prolamin tandemly arrayed genes in coix, sorghum and maize genomes.

Plant molecular biology·2010

Related Experiment Video

Updated: Sep 19, 2025

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.5K

Programmatically activated DNA hydrogel microcapsules for precision therapy in inflammatory bowel disease.

Peifen Lu1, Hongxiu Yuan1, Gang Wang1

  • 1Shandong Cancer Hospital and Institute, School of Life Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, China.

Theranostics
|June 16, 2025
PubMed
Summary

Programmatically activated DNA hydrogel microcapsules (HAMs) offer a novel, chemical-free therapeutic strategy for inflammatory bowel disease (IBD). This stable, biocompatible system precisely targets IBD lesions, reducing inflammation and improving gut health.

Keywords:
DNA hydrogelinflammation suppressioninflammatory bowel disease.multistage delivery microcapsulesoral microspheres

More Related Videos

Preparation of Multifunctional Silk-Based Microcapsules Loaded with DNA Plasmids Encoding RNA Aptamers and Riboswitches
10:07

Preparation of Multifunctional Silk-Based Microcapsules Loaded with DNA Plasmids Encoding RNA Aptamers and Riboswitches

Published on: October 8, 2021

1.5K
Magnetic and Thermal-sensitive PolyN-isopropylacrylamide-based Microgels for Magnetically Triggered Controlled Release
08:39

Magnetic and Thermal-sensitive PolyN-isopropylacrylamide-based Microgels for Magnetically Triggered Controlled Release

Published on: July 4, 2017

9.0K

Related Experiment Videos

Last Updated: Sep 19, 2025

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.5K
Preparation of Multifunctional Silk-Based Microcapsules Loaded with DNA Plasmids Encoding RNA Aptamers and Riboswitches
10:07

Preparation of Multifunctional Silk-Based Microcapsules Loaded with DNA Plasmids Encoding RNA Aptamers and Riboswitches

Published on: October 8, 2021

1.5K
Magnetic and Thermal-sensitive PolyN-isopropylacrylamide-based Microgels for Magnetically Triggered Controlled Release
08:39

Magnetic and Thermal-sensitive PolyN-isopropylacrylamide-based Microgels for Magnetically Triggered Controlled Release

Published on: July 4, 2017

9.0K

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Drug Delivery Systems

Background:

  • DNA nanomedicines show therapeutic promise but face challenges in chemical-free applications.
  • Developing effective treatments for inflammatory bowel disease (IBD) remains a significant clinical need.

Purpose of the Study:

  • To develop programmed activated DNA hydrogel microcapsules (HAMs) for targeted inflammatory bowel disease (IBD) therapy.
  • To create a stable, biocompatible, and chemical-free DNA nanomedicine for IBD treatment.

Main Methods:

  • Constructed HAMs by encapsulating ATP-responsive DNA hydrogels within sodium alginate microcapsules.
  • Utilized aptamer-functionalized tetrahedral DNA nanostructures (TDNs) for anti-inflammatory properties and targeted release.
  • Evaluated HAMs' performance in vitro and in vivo using a dextran sodium sulfate-induced colitis model.

Main Results:

  • HAMs demonstrated multistage response to intestinal conditions, positive charge at IBD lesions, and ATP-triggered release.
  • Achieved precise targeting of IBD lesions, reduced inflammatory cytokines, restored intestinal barrier function, and modulated gut microbiota.
  • Confirmed excellent stability and lack of significant long-term toxicity in treated mice.

Conclusions:

  • Programmatically activated HAMs represent a stable, specific, and biocompatible system for pure DNA nanostructure therapy.
  • This novel approach overcomes challenges in DNA nanomedicine development and shows promise for effective IBD treatment.